Search clinical trials for: BI 1356

Total 1429 results

Boehringer Ingelheim

Completed

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Hepatitis C, Chronic

United States, Brazil, France, Germany, Italy, Spain, Switzerland, United Kingdom
Wissenschaftliches Institut Bethanien e.V

Completed

Validation of a New Automatic Bi-level Algorithm in the Treatment of Sleep-disordered Breathing

Obstructive Sleep Apnea

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Healthy

Germany
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Breast Cancer

China
Boehringer Ingelheim

Completed

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

Healthy

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Acute Leukemia | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Systemic Mastocytosis | Recurrent Hematologic Malignancy | Hairy Cell Leukemia | Chronic... and other conditions
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants

Healthy Volunteer

Belgium
Imcyse SA

Terminated

IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) (IMPACT)

Diabetes Mellitus, Type 1

United Kingdom, United States, Australia, Lithuania, Belgium, Italy, Slovenia, Sweden
Boehringer Ingelheim

Completed

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

Asthma

United States
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058

Pulmonary Arterial Hypertension | Cardiovascular Disease+Pulmonary Disease

United Kingdom
The Miriam Hospital
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Planned Parenthood...

Completed

Women SHARE Study: Reducing Sexual Risk (HIV)

Sexually Transmitted Diseases | Alcohol and Substance-Related Mental Disorders

United States
Boehringer Ingelheim

Completed

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Alzheimer Disease

United States, Spain, Canada, United Kingdom, Germany, Italy, Netherlands, Portugal, Austria, Belgium, France, Poland
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety in Healthy Volunteers

Healthy

Belgium, New Zealand
Boehringer Ingelheim

Completed

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Psoriasis

United States, Canada, Finland, France, Germany, Norway, Sweden
University of Copenhagen

Completed

Probiotic Bacteria to Infants With Atopic Dermatitis

Atopic Dermatitis

Denmark
Texas Woman's University

Not yet recruiting

Benefits of Insoles With Real-Time Alert and Foot Self-Care Education

Diabetes Complications

United States
Boehringer Ingelheim

Completed

Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses

Healthy

Germany
Boehringer Ingelheim

Completed

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

Spain, United States, Korea, Republic of, Malaysia, Poland, Thailand, Bulgaria, Chile, Estonia, Germany, Hungary, New Zealand, Russian Federation, Serbia, Ukraine
University of California, San Francisco

Completed

The Effect of a Novel Audit and Feedback Bundle on Inpatient Performance

Quality Improvement

United States
Boehringer Ingelheim

Completed

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

Depressive Disorder, Major

Germany
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Solid Tumors, KRAS Mutation

Spain, United Kingdom, United States, Belgium
Beijing Tiantan Hospital

Completed

Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

Acute Ischemic Stroke | Mechanical Thrombectomy | Edaravone Dexborneol | Phase III

China
Boehringer Ingelheim

Completed

BI 671800 ED in Steroid-naive Asthmatic Patients

Asthma

United States, Australia, Canada, Colombia, Korea, Republic of, Mexico, New Zealand, Peru, Philippines, Taiwan
Biotronik SE & Co. KG

Recruiting

Post-market Clinical Follow-up Data Collection From Procedures With BIOTRONIK EP Products (BIO|COLLECT-EP)

Cardiac Arrhythmia

Germany
AbbVie
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Healthy

Japan, Korea, Republic of
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Solid Tumors, KRAS Mutation; SOS1

United States, Netherlands, Germany
Ankara City Hospital Bilkent

Completed

Efficacy of Bi-level ESPB Application in Patients Undergoing VATS

Pain, Postoperative | Erector Spinae Plane Block | Thoracic Surgery, Video-Assisted | Multimodal Analgesia

Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

Healthy

Germany
University Hospital, Basel, Switzerland

Completed

Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Humans

Endocrine System Diseases

Switzerland
Sir Run Run Shaw Hospital

Recruiting

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Rectal Adenocarcinoma

China
Dr. Yoram Shir
McGill University; Louise & Alan Edwards Foundation

Terminated

The Effect of Soy Protein on Neuropathic Pain

Neuralgia

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Boehringer Ingelheim

Terminated

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Psychotic Disorders

United States, Canada, United Kingdom, China
Boehringer Ingelheim

Completed

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

Hepatitis C

United States
Xiangya Hospital of Central South University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke (EARLYS)

Ischemic Stroke, Acute | Treatment Outcome

China
Suez Canal University
National Research Centre, Egypt

Completed

Outcome of Preserved Mitral Valve Apparatus During Mitral Valve Replacement (EarlyOutcome)

Mitral Valve Replacement | Diseases of Mitral Valves | Abnormality of Mitral Valve Annulus (Disorder)

Egypt
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight

Obesity

Germany
University of Oxford
University of Copenhagen; Zimmer Biomet

Unknown

All Ligaments Left In Knee Arthroplasty Trial (ALLIKAT)

Primary Osteoarthritis of Knee Nos

United Kingdom
Boehringer Ingelheim

Terminated

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Non-Hodgkin

Austria, Belgium, United States, Bulgaria, Croatia, Czech Republic
Boehringer Ingelheim

Completed

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States, Spain, Germany, Italy
Keming Gao
University of Michigan; Case Western Reserve University; University of Toledo...

Completed

Project Guard: Reducing Alcohol Misuse/Abuse in the National Guard

Alcohol Use

United States
Chinese University of Hong Kong

Completed

Herbal Treatment for Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

Hong Kong
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Mian XI

Recruiting

Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) (HSBRT2401)

Hepatocellular Carcinoma

China
Onconic Therapeutics Inc.

Recruiting

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Erosive Esophagitis

Korea, Republic of

Search clinical trials for: BI 1356

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations